Chronic subcutaneous infusion therapy with apomorphine in advanced Parkinson's disease compared to conventional therapy: A real life study of non motor effect

Journal of Parkinson's Disease

Volumn 1, Issue 2, 2011, Pages 197-203

  Martinez Martin, Pablo ^a   Reddy, Prashanth ^f   Antonini, Angelo ^b   Henriksen, Tove ^c   Katzenschlager, Regina ^d   Odin, Per ^e   Todorova, Antonia ^f   Naidu, Yogini ^g   Tluk, Susanne ^g   Chandiramani, Chandni ^f   Martin, Anne ^f   Chaudhuri, Kallol Ray ^f,g  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

^b IRCCS SAN CAMILLO HOSPITAL   (Italy)

^c BISPEBJERG HOSPITAL   (Denmark)

^d SMZ Ost Donauspital ^*  (Austria)

^e Central Hospital   (Germany)

^f KING S COLLEGE HOSPITAL   (United Kingdom)

^g UNIVERSITY HOSPITAL LEWISHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

APOMORPHINE; LEVODOPA;

ADULT; AGED; ALLOPATHY; ARTICLE; CHRONIC DRUG ADMINISTRATION; CLINICAL ARTICLE; CLINICAL FEATURE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DISEASE SURVEILLANCE; DRUG EFFECT; FATIGUE; FOLLOW UP; HUMAN; HYPERHIDROSIS; ILLUSION; INFUSION; INTENTION TO TREAT ANALYSIS; INTERMETHOD COMPARISON; MOTOR PERFORMANCE; NOCTURIA; PARANOIA; PARKINSON DISEASE; PRIORITY JOURNAL; PSYCHOLOGICAL RATING SCALE; QUALITY OF LIFE; QUESTIONNAIRE; URINARY URGENCY; VISUAL HALLUCINATION;

AGED; APOMORPHINE; CHI-SQUARE DISTRIBUTION; DOPAMINE AGONISTS; DRUG ADMINISTRATION ROUTES; FEMALE; HUMANS; INFUSIONS, SUBCUTANEOUS; MALE; MIDDLE AGED; OBSERVATION; PARKINSON DISEASE; PILOT PROJECTS; QUALITY OF LIFE; SEVERITY OF ILLNESS INDEX;

EID: 80054862205     PISSN: 18777171     EISSN: 1877718X     Source Type: Journal    
DOI: 10.3233/JPD-2011-11037     Document Type: Article

References (36)

1. Lees A, & Turner K (2002) Apomorphine for Parkinson's disease. Practical Neurology, 2, 280-286.
2. Poewe W, & Wenning GK (2000) Apomorphine: An underutilized therapy for Parkinson's disease. Mov Disord, 15(5), 789-794.
3. Chaudhuri KR, & Clough C (1998) Subcutaneous apomorphine for Parkinson's disease, Effective yet underused. British Medical Journal, 316, 641. (Pubitemid 28121017)
4. National Institute for Health and Clinical Excellence. Clinical Guideline 35 Parkinson's disease: Diagnosis and management in primary and secondary care (2006) Available at: http://www.nice.org.uk/nicemedia/pdf/cg035niceguideline.pdf Accessed. 27 June, 2010.
5. Grosset DG, Macphee GJA, & Nairn M (2010) On behalf of the Guideline Development Group. Diagnosis and pharmacological management of Parkinson's disease: Summary of SIGN guidelines. BMJ, 340, b5614.
6. Katzenschlager R, Hughes A, Evans A, Manson AJ, Hoffman M,&Swinn L et al. (2005) Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: A prospective study using single-dose challenges. Mov Disord, 20(2), 151-157. (Pubitemid 40361117)
7. Manson AJ, Turner K, & Lees AJ (2002) Apomorphine monotherapy in the treatment of refractory motor complications of Parkinson's disease: Long-term follow-up study of 64 patients. Mov Disord, 17(6), 1235-1241. (Pubitemid 36041337)
8. Garcia Ruiz P, Ignacio SA, Pensando BA, Garcia AC, Frech FA, & Lopez MA et al. (2008) Efficacy of long term continuous subcutaneous apomorphine infusion in advanced Parkinson's disease with motor fluctuations: A multicenter study. Mov Disord, 23(8), 1130-1136.
9. Stocchi F, Vacca L, De Pandis MF, Barbato L, Valente M, & Ruggieri S (2001) Subcutaneous continuous apomorphine infusion in fluctuating patients with Parkinson's disease: Long term results. Neurol Sci, 22, 93-94. (Pubitemid 32622278)
10. PoeweW, Kleedorfer B,Wagner M, Bosch S, & Schelosky L (1993) Continuous subcutaneous apomrophine infusions for fluctuating Parkinson's disease. Long term follow up in 18 patients. Adv Neurol, 60, 656-659.
11. Martinez-Martin P, Todorova A, Odin P, Henriksen T, Naidu Y, Tluk et al. (2010) The tolerability of apomorphine infusion in advanced Parkinson's patients with hallucinations and gastrointestinal non motor symptoms: Implications for treatment. A EUROPAR study. Mov Disord, 25(Suppl 2), S421.
12. Naidu Y, Logishetty K, Martin A, Tluk S, Reddy P, Martinez- Martin P, Odin P, Henriksen T, & Chaudhuri KR (2009) Efficacy of apomorphine infusion onmoodand depression aspects of non-motor symptoms in advanced Parkinson's disease? Park Rel Disord, 15(Suppl 2), S130 (P2.149).
13. Chaudhuri KR, Martinez-Martin P, Brown RG, Sethi K, Stocchi F, & Odin P et al. (2007) The metric properties of a novel non-motor symptoms scale for Parkinson's disease: Results from an international pilot study. Mov Disord, 22, 1901-1911. (Pubitemid 350134203)
14. Martinez-Martin P, Rodriguez-Blazquez C, Abe K, Bhattacharyya KB, Bloem BR, & Carod-Artal FJ et al. (2009) International study on the psychometric attributes of the nonmotor symptoms scale in Parkinson disease. Neurology, 73, 1584-1591.
15. Hughes AJ, Daniel SE, Kilford L, & Lees AJ (1992) Accuracy of clinical diagnosis of idiopathic Parkinson's disease: A clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry, 55, 181-184.
16. Fahn S,&Elton RL (1987) Members of the UPDRS Development Committee. Unified Parkinson's disease Rating Scale. En: Fahn S, Marsden CD, Calne DB, Goldstein M, eds. Recent developments in Parkinson's disease, Macmillan Healthcare Information, Florham Park, NJ. 2, 153-164.
17. Hoehn MM, & Yahr MD (1967) Parkinsonism: Onset, progression, and mortality. Neurology, 17, 427-442.
18. Jenkinson C, Fitzpatrick R, Peto V, Greenhall R, & Hyman N (1997) The PDQ-8: Development and validation of a shortform Parkinson's disease questionnaire. Psychol Health, 12, 805-814.
19. Benjamini Y, & Hochberg Y (1995) Controlling the false discovery rate: A practical and powerful approach to multiple testing. J Roy Statistical Society, 57, 289-300.
20. Swinscow TDV (1997) Correlation and Regression, BMJ Publishing Group, Statistics at square one, 9th edition. University of Southampton.
21. Kazis L, Anderson J, & Meenan R (1989) Effect sizes for interpreting changes in health status. Med Care, 27(Suppl), 178-189.
22. Husted JA, Cook RJ, Farewell WT, & Gladman DD (2000) Methods for assessing responsiveness: A critical review and recommendations. J Clin Epidemiol, 53, 459-468.
23. Crosby RD, Kolotkin RL, & Williams GR (2003) Defining clinically meaningful change in health-related quality of life. J Clin Epidemiol, 56, 395-407.
24. Guyatt GH, Osoba D,Wu AW,Wyrwich K, Norman G (2002) The Clinical Significance Consensus Meeting Group Methods to explain the clinical significance of health status measures. Mayo Clin Pro, 77, 371-383. (Pubitemid 34260746)
25. Schünemann HJ, Akl EA, & Guyatt GH (2006) Interpreting the results of patients reported outcome measures in clinical trials: The clinicians perspective. Health Qual Life Outc, 4, 62.
26. Wyrwich KW, Bullinger M, & Aaronson N et al. (2005) Estimating clinically significant differences in quality of life outcomes. Qual Life Res, 14, 285-295. (Pubitemid 40576381)
27. Rejas J, Pardo A, & Ruiz MA (2008) Standard error of measurement as a valid alternative to minimally important difference for evaluating the magnitude of changes in patientreported outcomes measures. J Clin Epidemiol, 61, 350-356. (Pubitemid 351308068)
28. Honig H, Antonini A, Martinez-Martin P, Forgacs I, Faye GC, & Fox T et al. (2009) Intrajejunal levodopa infusion in Parkinson's disease: A pilot multicenter study of effects on nonmotor symptoms and quality of life. Mov Disord, 24(0), 1468-1474.
29. van Laar T, Postma AC, & Drent M (2010) Continuous subcutaneous infusion of Apomorphine can be sued safely in patients with Parkinson's disease and pre-existing visual hallucinations. Parkinsonism Relat Disord, 16, 71-72.
30. Tamminga CA, Schaffer MH, Smith RC, & Davis JM (1978) Schizophrenic symptoms improve with apomorphine. Science, 200, 567-568. (Pubitemid 8350342)
31. Ellis C, Lemmens G, Parkes JD, Abbott RJ, Pye IF, & Leigh PN et al. (1997) Use of apomorphine in Parkinsonian patients with neuropsychiatric complications to oral treatment. Parkinsonism Relat Disord, 3(2), 103-107. (Pubitemid 28090190)
32. Witjas T, Kaphan E, Azulay JP, Blin O, Ceccaldi M, Pouget J, Poncet M, & Chérif AA (2002) Nonmotor fluctuations in Parkinson's disease: Frequent and disabling. Neurology, 59(3), 408-413. (Pubitemid 34857934)
33. Reuter I, Ellis CM, & Chaudhuri KR (1999) Nocturnal subcutaneous apomorphine infusion in Parkinson's disease and restless legs syndrome. Acta Neurol Scand, 100, 163-167. (Pubitemid 29376827)
34. Relton C, Togerson D, O'Cathain AO, & Nicholl J (2010) Rethinking pragmatic randomised controlled trials: Introducing the cohort multiple randomised controlled trial design. BMJ, 340, 963-967.
35. De Gaspari D, Siri C, Landi A, Cilia R, Bonetti A, & Natuzzi F et al. (2006) Clinical and neuropsychological follow up at 12 months in patients with complicated Parkinson's disease treated with subcutaneous apomorphine infusion or deep brain stimulation of the subthalamic nucleus. J Neurol Neurosurg Psychiatry, 77(4), 450-453.
36. Nyholm D (2009) Comparison of apomorphine and levodopa infusions in four patients with Parkinson's disease with symptom fluctuations. Acta Neurol Scand, 119(5), 345-348.